Mitotane is the systemic therapy most specifically directed at adrenocortical disease. Unlike cytotoxic agents that attack dividing cells broadly, mitotane acts on the adrenal cortex itself — accumulating selectively in adrenal tissue, suppressing steroid hormone production, and exerting a direct toxic effect on adrenocortical cells. This dual adrenolytic and steroidogenesis-inhibiting profile explains both its therapeutic role in adrenocortical carcinoma and its management of cortisol excess. Understanding the enzymatic steps it disrupts clarifies why dosing and monitoring are so central to safe use. Because the drug's activity is both tissue-selective and enzyme-specific, mitotane occupies a distinctive niche among agents directed at endocrine tumors rather than a broadly cytotoxic profile.
A defining feature of mitotane is its preferential uptake by the adrenal cortex. Research points to sterol O-acyltransferase 1 (SOAT1) as a key mediator: SOAT1 is highly expressed in adrenal tissue and facilitates mitotane accumulation there, concentrating the drug where it is needed while sparing most other organs. This tissue selectivity underpins the agent's adrenolytic character and distinguishes its mechanism from conventional chemotherapy.
Mitotane interferes with the enzymatic cascade that produces adrenal steroids. It inhibits CYP11A1 (cholesterol side-chain cleavage, also called P450scc), the first and rate-limiting step converting cholesterol to pregnenolone, and it suppresses CYP11B1 (11β-hydroxylase), which converts 11-deoxycortisol to cortisol. By blocking these enzymes, mitotane reduces cortisol and other adrenal steroid output, which is the basis for its use in controlling hormone excess as well as its antitumor effect.
Beyond enzyme inhibition, mitotane is directly toxic to adrenocortical cells, producing cortical atrophy over time. This cytotoxic action contributes to tumor control in adrenocortical carcinoma but also means adrenal insufficiency is a expected management consideration, often requiring glucocorticoid and mineralocorticoid replacement during therapy. The mechanism therefore demands careful dosing titration and endocrine monitoring.
Q: How does mitotane reach the adrenal gland selectively? A: It accumulates preferentially in adrenal tissue, a process linked to high SOAT1 expression there, which concentrates the drug in the cortex.
Q: Which steroidogenesis enzymes does mitotane affect? A: It inhibits CYP11A1 (cholesterol side-chain cleavage) and CYP11B1 (11β-hydroxylase), reducing cortisol and other adrenal steroid production.
Q: Why is hormone replacement needed during therapy? A: Mitotane suppresses steroidogenesis and atrophies adrenocortical tissue, so glucocorticoid and sometimes mineralocorticoid replacement is typically required.
Q: What formulation is referenced for this product? A: The 500 mg tablet strength supplied in a 100-tablet pack is the configuration referenced for this product.
Mitotane is the systemic therapy most specifically directed at adrenocortical disease. Unlike cytotoxic agents that attack dividing cells broadly, mitotane acts on the adrenal cortex itself — accumulating selectively in adrenal tissue, suppressing steroid hormone production, and exerting a direct toxic effect on adrenocortical cells. This dual adrenolytic and steroidogenesis-inhibiting profile explains both its therapeutic role in adrenocortical carcinoma and its management of cortisol excess. Understanding the enzymatic steps it disrupts clarifies why dosing and monitoring are so central to safe use. Because the drug's activity is both tissue-selective and enzyme-specific, mitotane occupies a distinctive niche among agents directed at endocrine tumors rather than a broadly cytotoxic profile.
A defining feature of mitotane is its preferential uptake by the adrenal cortex. Research points to sterol O-acyltransferase 1 (SOAT1) as a key mediator: SOAT1 is highly expressed in adrenal tissue and facilitates mitotane accumulation there, concentrating the drug where it is needed while sparing most other organs. This tissue selectivity underpins the agent's adrenolytic character and distinguishes its mechanism from conventional chemotherapy.
Mitotane interferes with the enzymatic cascade that produces adrenal steroids. It inhibits CYP11A1 (cholesterol side-chain cleavage, also called P450scc), the first and rate-limiting step converting cholesterol to pregnenolone, and it suppresses CYP11B1 (11β-hydroxylase), which converts 11-deoxycortisol to cortisol. By blocking these enzymes, mitotane reduces cortisol and other adrenal steroid output, which is the basis for its use in controlling hormone excess as well as its antitumor effect.
Beyond enzyme inhibition, mitotane is directly toxic to adrenocortical cells, producing cortical atrophy over time. This cytotoxic action contributes to tumor control in adrenocortical carcinoma but also means adrenal insufficiency is a expected management consideration, often requiring glucocorticoid and mineralocorticoid replacement during therapy. The mechanism therefore demands careful dosing titration and endocrine monitoring.
Q: How does mitotane reach the adrenal gland selectively? A: It accumulates preferentially in adrenal tissue, a process linked to high SOAT1 expression there, which concentrates the drug in the cortex.
Q: Which steroidogenesis enzymes does mitotane affect? A: It inhibits CYP11A1 (cholesterol side-chain cleavage) and CYP11B1 (11β-hydroxylase), reducing cortisol and other adrenal steroid production.
Q: Why is hormone replacement needed during therapy? A: Mitotane suppresses steroidogenesis and atrophies adrenocortical tissue, so glucocorticoid and sometimes mineralocorticoid replacement is typically required.
Q: What formulation is referenced for this product? A: The 500 mg tablet strength supplied in a 100-tablet pack is the configuration referenced for this product.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
